Literature DB >> 28950333

Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.

C Messina1,2, M Messina3, E Zanardi1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28950333     DOI: 10.1093/annonc/mdx530

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review.

Authors:  Baha' Sharaf; Rama AlMasri; Nayef Abdel-Razeq; Osama Salama; Ibrahim Hamad; Mahmoud Abunasser; Hikmat Abdel-Razeq
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-01-05

2.  Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study.

Authors:  Judith J Stephenson; Jonathon Colby Gable; Rebekah Zincavage; Gregory L Price; Collin Churchill; Emily Zhu; Keri Stenger; Mukul Singhal; Bal Nepal; Michael Grabner; Michael J Fisch; David Debono; Amy R Geschwender; Gebra Cuyun Carter
Journal:  Patient Prefer Adherence       Date:  2021-11-03       Impact factor: 2.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.